Data set | Procedure | What's in this data set | Panel | Sex | Age (weeks) | Year |
---|---|---|---|---|---|---|
|
glucose tolerance
with high-fat high-sucrose diet |
Area under curve. | DO population | both | 4-26wks | 2018 |
|
glucose tolerance
with high-fat diet |
Glucose post oral gavage: 0, 15, 30, 45, 60, 90, 120, 150, 180 min plus area under curve. | BXD w/par (57) | m | 8-29 wks | 2016 |
|
glucose tolerance
with high-fat diet |
Plasma glucose levels: 0, 15, 30, 45, 60, 90, 120, 150, and 180 min, post oral gavage following overnight fast. | inbred w/CC8 | both | 8-21 wks | 2021 |
|
glucose tolerance
with high-fat diet |
High-fat diet vs. control. 0 to 120 min after 20% glucose i.p. 18h fast. | DO population | both | 8,19wks | 2015 |
|
glucose tolerance
with high-fat diet |
High-fat diet (17wks) vs. control. 0 to 120 min after 10% glucose i.p. 4h fast. | LGXSM w/par (19) | both | 12-16wks | 2004 |
|
glucose tolerance | 0 to 180 min after 20% glucose i.p. 16h fast. | inbred (4) | both | 12, 24, 52 wks | 2008 |
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | inbred w/CC8 (6) | both | 13-14wks | 2020 |
|
glucose tolerance
with (R/S)-1,3-butanediol, 17-a-estradiol, 17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride, 2-(2-Hydroxyphenyl)benzoxazole, 3-(3-hydroxybenzyl)-5-methylbenzo[d]oxazol-2(3H)-one, 4-OH-a-phenyl-N-tert-butyl nitrone, 4-phenylbutyrate, acarbose, aspirin, astaxanthin, b-guanidinopropionic acid, caffeic acid phenethyl ester, canagliflozin, captopril, candesartan cilexetil, curcumin, dimethyl fumarate, enalapril, fisetin, fish oil, geranylgeranyl acetone, glycine, green tea extract, INT-767 FXR/TGR5 agonist, inulin, L-Leucine, meclizine, medium-chain triglyceride, metformin, metformin plus rapamycin, methylene blue, minocycline, MitoQ, mycophenolic acid, nicotinamide riboside, nitroflurbiprofen, nordihydroguaiaretic acid, oxaloacetic acid, PB125, protandim, rapamycin, rapamycin plus acarbose, resveratrol, SG1002, simvastatin, sulindac, syringaresinol, TM5441, ursodeoxycholic acid, ursolic acid, 16-a-hydroxyestriol, 2,4-dinitrophenol, a-Ketoglutarate, Hydralazine, Nebivolol, Sodium thiosulfate |
Postprandial glucose. Invervention vs. controls. | UM-HET3 population | both | various | 2004-2024 |
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | KOMP | both | 8-18wks | 2021 |
|
glucose tolerance | 0 to 120 min after 20% glucose i.p., 16h fast. | KOMP | both | 66-81wks | 2021 |
|
study archive
with rosiglitazone |
Effect of rosiglitazone peptide on diet-induced obesity, type 2 diabetes. |
one strain: BKS.Cg-Dock7 |
m | 2009 | |
|
glucose tolerance | 0 to 120 min after 10% glucose i.p. 5h fast. | inbred (11) | both | 8-10wks | 2005 |
|
glucose tolerance
with high-fat diet |
Plasma glucose levels at 0, 30, 60 min post oral gavage of Ensure Plus, overday fast. | BXD w/par (36) | m | 8-29 wks | 2022 |
|
glucose tolerance
with high-fat high-sucrose diet |
0-180 min after 20% glucose i.p. at 23-24 wks of age. 15h fast. | DO population | both | 3-30 wks | 2020 |